Answers are grounded in this paper and cite their sources.
PROCEEDINGS On July 23, 2022, BreastGlobal organised a webinar on ‘Sentinel Lymph Node Biopsy (SLNB) in Breast Cancer: Why, How, When and New Frontiers,’ moderated by Mr. Ashutosh Kothari (Oncoplastic & Reconstructive Breast Surgeon, Guy’s and St Thomas NHS Foundation Trust, London; BG Co-Chair) and Dr. Urvashi Jain (Fellow, Oncoplastic & Reconstructive Breast Surgeon, Guy’s and St Thomas NHS Foundation Trust, London) and chaired by Dr. C.B. Koppiker (Breast, Oncoplastic & Reconstruction Surgeon, & Medical Director, Orchids Breast Health, Pune, India, & BG Co-Chair) and Professor Chintamani (Head, Surgery, VMMC, Safdarjung Hospital, New Delhi, India; BG Co-Chair; & President, ASOMA). There were over 400 attendees for the webinar. Following is the synopsis of the webinar in proceedings format. The recording is available on BreastGlobal website: https://breastglobal.org/courses/sentinel-node-biopsy-slnb-in-breast-cancerwhy-how-when-and-new-frontiers/. The webinar had four talks followed by a panel discussion. Talk 1: Do all patients need a sentinel lymph node biopsy? By Dr. Michael Knauer, Head of Breast Surgery, Tumour & Brustzentrum, St. Gallen, Switzerland Dr. Michael Knauer initiated the talk by providing a concise overview of the evolution of axillary surgery. He raised two critical questions regarding the future of this approach. The first question was whether axillary lymph node dissection should be omitted even for patients with positive SLNB, referring to the Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS) trial.[1] The second question posed was whether SLNB should be omitted for low-risk, cN0 patients, citing the SOUND INSEMA trial.[2] The speaker delved into the existing accepted guidelines for axillary staging and emphasised that ultrasound and biopsy are the most sensitive methods, with SLNB currently considered the gold standard. Dr. Knauer provided a brief description of the indications and the two primary strategies employed for axillary staging. Dr. Knauer proceeded to discuss the NCCN guidelines for axillary node staging in invasive breast cancer. He reviewed various trials that assessed the utility and indications for SLNB. He highlighted that despite the recognition of overtreatment in the axilla, there is still no consensus on routine imaging of the axilla. The reduction of axillary treatment may potentially lead to decreased morbidity, he emphasised. The speaker pointed out that although SLNB is presently considered the gold standard for axillary staging, it can be avoided in select patients. He concluded his talk by stating that ongoing studies will contribute to a better understanding of the reduced morbidity associated with this approach. Overall, Dr. Michael Knauer’s talk shed light on the necessity of SLNB in all patients and the ongoing efforts to refine axillary staging, reduce overtreatment and minimise associated morbidity in breast cancer patients. Talk 2: Sentinel lymph node biopsy in ductal carcinoma in situ: When and why Speaker: Dr. Andreas Karakatsanis, Senior Consultant, Clinical Lead, Breast, Section for Breast & Endocrine Surgery, Uppsala University Hospital, Sweden. Dr. Andreas Karakatsanis commenced his talk by expressing his recommendation against SLNB in most patients diagnosed with ductal carcinoma in situ (DCIS). According to current guidelines, SLNB should be considered only when a mastectomy is planned for extensive DCIS. He emphasised that the risk of an undiagnosed underlying invasive cancer in cases of extensive DCIS is low. The SentiNot study suggests the use of the superparamagnetic iron oxide (SPIO) technique for SLNB following histological evaluation of mastectomy tissue in such situations.[3] Dr. Karakatsanis stressed that while SLNB in DCIS may impact morbidity, it does not affect survival. The speaker drew attention to the inadequacy of existing guidelines in accurately identifying DCIS patients who would benefit from upfront SLNB. Therefore, he underscored the importance of conducting evidence-based studies and trials to reevaluate and refine these guidelines. Dr. Andreas Karakatsanis’ talk primarily focussed on the limited recommendation for SLNB in most patients with DCIS and the necessity for further research to enhance the current guidelines. He discussed the potential use of the SPIO technique and highlighted the ongoing SentiNot 2.0 trial,[4] which aims to provide additional insights into the role of SLNB in DCIS. Overall, Dr. Karakatsanis’ presentation shed light on the current understanding and challenges associated with SLNB in patients with DCIS, emphasising the need for evidence-based studies and trials to guide clinical decision-making and refine the guidelines in this specific context. Talk 3: Sentinel lymph node biopsy after neoadjuvant chemotherapy Speaker: Dr. Yazan Masannat, Consultant Oncoplastic Breast Surgeon, NHS Grampian, and Founder and Editor of the popular iBreastBook. Mr. Yazan Masannat presented a talk on the scenarios for performing SLNB in patients who have undergone neoadjuvant chemotherapy (NACT). He discussed two significant trials in this context, the AXSANA trial and the axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy (ATNEC) trial. The AXillary Surgery After NeoAdjuvant Treatment (AXSANA) trial[5] is a prospective multicenter cohort study that aims to evaluate different surgical methods of axillary staging, including SLNB, targeted axillary dissection (TAD) and axillary dissection in clinical node-positive patients who have received NACT. Mr. Masannat provided an overview of the trial, emphasising the importance of assessing the most effective surgical approach for axillary staging in this specific patient population.FigureHe also mentioned the ATNEC trial,[6] which focuses on the axillary management of breast cancer patients with biopsy-proven nodal metastasis at presentation who undergo NACT. The trial aims to provide insights into the optimal approach for axillary treatment in N1 breast cancer patients after NACT. Mr. Masannat summarised the current accepted practices for determining when to perform or omit SLNB in patients after NACT, as seen in the figure. The speaker provided valuable insights into the challenges and considerations surrounding SLNB in patients who have undergone NACT. By discussing ongoing trials such as AXSANA and ATNEC,[5,6] he highlighted the importance of evidence-based research in guiding clinical decision-making and optimising axillary management in this specific patient population. Overall, Mr. Yazan Masannat’s talk emphasised the need for further research and evidence to determine the most appropriate approach for axillary staging and treatment in breast cancer patients who have received NACT, shedding light on the ongoing trials and current practices in this field. Talk 4: New techniques for sentinel lymph node biopsy in breast cancer surgery Speaker: Dr. Chi Wei Mok, Consultant Oncoplastic & Minimally Invasive Breast Surgeon, Changi General Hospital, Singapore. Dr. Chi Wei Mok delivered a talk on the new techniques for performing SLNB in breast cancer surgery. He began by discussing the commonly used dual technique for SLNB, which involves the use of radioactive colloid in combination with blue dye. While this technique has shown good identification rates and lower false-negative rates, Dr. Mok highlighted the inherent disadvantages associated with its use. The speaker then moved on to discuss novel techniques currently being studied for SLNB. These techniques include indocyanine green fluorescence (ICG), SPIO nanoparticles, contrast-enhanced ultrasound imaging using microbubbles and computed tomography/magnetic resonance lymphography. Dr. Mok elaborated on the advantages and potential applications of these techniques in SLNB. Dr. Mok further described his own work on a network meta-analysis that compared the novel and conventional SLNB techniques in breast cancer, citing the relevant publication[7] The analysis identified ICG as the technique with the lowest false-negative rate. He shared his experience using ICG in his practice, noting that it resulted in a 25% higher yield of positive lymph nodes compared with blue dye. The speaker then discussed his technique called endoscopic-assisted ICG and its advantages, as detailed in a publication.[8] Dr. Mok emphasised the strengths of ICG, such as its ease of use, improved visualisation, higher lymph node yield and affordability. However, he also emphasised the importance of conducting cost-effectiveness analyses to determine the long-term sustainability of these techniques. In summary, Dr. Chi Wei Mok’s talk provided insights into the new techniques for SLNB in breast cancer surgery. He highlighted the limitations of the conventional dual technique and discussed the potential benefits and applications of novel techniques such as ICG. By sharing his own experiences and research findings, Dr. Mok underscored the potential advantages and strengths of ICG in improving SLNB outcomes. PANEL DISCUSSION The webinar concluded with a novel approach toward a panel discussion that comprised all the speakers, co-charis and invited esteemed panellists, Dr. Tibor Kovács (Medical Director, Breast Health & Chief of Breast Surgery, Jiahui International Hospital, China), Dr. Bahadir Gulluoglu (Professor, Department of Surgery, Breast Surgery Unit, Marmara University School of Medicine and President SENATURK Turkish Academy of Senology) and Radiologist, Dr. Beenu Varghese (Lead Radiologist, Orchids Breast Health, Pune, India). The panel discussion was based on case scenarios that were previously circulated as a poll among BreastGlobal members and colleagues in the breast oncology community. The aim of the poll was to gather insights into current clinical practices. The results of the poll were then discussed with the panellists. The panellists engaged in a comprehensive discussion, offering their perspectives and expertise on the scenarios presented. We present each case scenario and associated discussion in the following. Scenario 1 [Figure 1] A screen-detected case of DCIS with extensive microcalcifications on mammography and proven intermediate and high-grade DCIS only on vacuum-assisted biopsy, planned for a mastectomy. The question posed to the panellists was whether they would consider performing SLNB at the same time as the mastectomy, given the availability of Magtrace (SPIO) at their centre.Figure 1: Clinical case scenario: 1Poll results The poll results indicated that 76.7% of the participants voted ‘yes’ for considering SLNB at the same time as the mastectomy, whereas 19.6% voted ‘no,’ and the remaining responses were ‘maybe.’ During the panel discussion, the current guidelines suggesting SLNB for DCIS undergoing mastectomy were mentioned. However, Dr. Karakatsanis, based on his SentiNot Trial,[4] expressed his opinion that unnecessary SLNB can be avoided in this scenario. Prof. Tibor Kovács supported this viewpoint and mentioned that Dr. Karakatsanis’s study could potentially bring about a change in clinical practice. He also acknowledged that factors such as affordability currently influence the decision to perform SLNB in such cases. The discussion surrounding case 1 highlighted the divergence of opinions among the panellists regarding the necessity of SLNB in screen-detected DCIS cases planned for mastectomy. While the majority of poll respondents were in favour of considering SLNB, the SentiNot Trial findings and the mention of affordability as a contributing factor added further nuances to the discussion. Scenario 2 [Figure 2] A 37-year-old woman presented with a 1.7-cm unifocal tumour in the left breast, showing no clinical or ultrasound evidence of axillary involvement. The tumour had characteristics of grade 2 nonspecial type (NST), estrogen receptor 8 (ER8), progesterone receptor 8 (PR8) and human epidermal growth factor receptor 2 (HER2)-negative. A privately done positron emission tomography (PET) scan revealed a suspicious 5-mm left internal mammary lymph node (IMLN). The patient is scheduled for a left-wide local excision (WLE) of the primary tumour. The question posed to the panellists was how they would address the axilla and potentially +/− extranodal sitesFigure 2: Clinical case scenario: 2Poll results The poll results indicated the following distribution among the respondents: 43.6% voted for left SLNB + radiation therapy (RT) to the left IMLN; 26.3% voted for left SLNB + RT to extranodal sites, including the supraclavicular fossa (SCF) and IMLN; 24.8% voted for left SLNB only; and 5.3% voted for left axillary clearance. During the discussion, all panellists unanimously agreed that it would be appropriate to ignore the PET scan result, considering it would likely lead to overdiagnosis. Prof. Bahadir provided an algorithm for his approach to this case. As the tumour was a 1.7-cm luminal A tumour with a low likelihood of metastasis (1%–2%), he would first perform SLNB. Depending on the SLNB results, if the nodes were positive, he would recommend radiating the extranodal sites, including the SCF and IMLN. The panel discussion highlighted the different opinions and approaches in addressing the axilla and potential extranodal sites in a specific case scenario. The majority of the respondents favoured SLNB with or without RT, whereas a small percentage opted for axillary clearance. The panellists emphasised the importance of considering tumour characteristics and nodal status in determining the appropriate management strategy. Scenario 3 [Figure 3] The case presented was that of a patient with right inflammatory breast cancer and one abnormal ipsilateral axillary lymph node, which was biopsy-proven to be metastatic and clipped. The patient received NACT and achieved a complete response in the axilla. She is now scheduled for a right mastectomy. The question posed to the panellists was how they would address the axilla in this scenario.Figure 3: Clinical case scenario: 3Poll results The poll results indicated the following distribution among the respondents: 48.1% voted for right TAD + SLNB, 44.4% voted for right axillary clearance and 7.5% voted for right SLNB alone. During the discussion, both Prof. Tibor and Prof. Bahadir expressed their preference for SLNB + TAD in this case, acknowledging that TAD is considered a contraindication for inflammatory breast cancer. However, they suggested that in cases where there is a complete response to NACT, SLNB + TAD can serve as a middle ground between only SLNB and total axillary clearance. They noted that the decision to perform SLNB + TAD depends on the surgeon’s experience and the availability of resources. If these conditions are not met, they recommended sticking to the accepted standard of care. The panel discussion highlighted the differing opinions regarding the optimal approach to addressing the axilla in a case of inflammatory breast cancer with a complete response to NACT. While some favoured SLNB + TAD as a potential middle ground, others preferred axillary clearance. The discussion emphasised the importance of individualised treatment decisions, considering factors such as the patient’s response to NACT and the surgeon’s expertise. Scenario 4 [Figure 4] The case presented was that of a patient with right breast cancer (T2N0M0) at presentation, ER 8, PR 7 and HER2 neu positive. The patient received NACT and showed a partial radiological response in the breast. Subsequently, she underwent right WLE and SLNB. The final histopathology revealed 8-mm residual grade 2 NST cancer that was completely excised, and SLNB showed isolated tumour cells in one of three lymph nodes.Figure 4: Clinical case scenario: 4Poll results The poll results indicated the following distribution among the respondents: 33.8% voted for right axillary nodal clearance, 32.3% voted for RT to the right axilla and 33.8% voted for no further intervention. During the discussion, it was highlighted that this scenario is currently a topic of debate. The panellists mentioned the ongoing studies and consensus meetings aimed at establishing a common standard for such cases. The differing opinions reflected the need for further research and evidence-based guidelines to determine the optimal approach for the axilla in this specific situation. The panel discussion underscored the complexity of managing residual disease in the axilla after partial response to NACT. The lack of a clear consensus highlighted the ongoing efforts to gather more data and reach a consensus on the appropriate management strategy. Scenario 5 [Figure 5] The case presented was a patient with right breast cancer (T2N1M0), unifocal disease at presentation, grade 3 NST, triple-negative breast cancer (TNBC) and two abnormal lymph nodes in the left axilla. The patient expressed a desire for breast conservation. The plan was to administer NACT with the goal of downsizing the primary tumour for breast-conserving surgery. The question was how to manage and plan the axilla in this case.Figure 5: Clinical case scenario: 5Poll results The poll results for case 5 showed the following distribution among the respondents: 75.2% voted to clip the lymph nodes with a view to perform TAD and SLNB based on the response to NACT, 22.6% voted for left axillary clearance and 2.3% voted for left SLNB only. Scenario 6 [Figure 6] The scenario presented was the continuation of the previous case (case 5), where the patient received NACT and showed a complete radiological response in the breast and axilla. The axillary lymph node that was previously biopsy-proven to be metastatic was clipped before NACT. The plan was to perform left WLE, and the question was how to address the axilla in this scenario.Figure 6: Clinical case scenario: 6Poll results The poll results for scenario 6 showed the following distribution among the respondents: 73.7% voted for left TAD + SLNB, 15% voted for left axillary clearance and 11.3% voted for left SLNB only. During the discussion, the panellists agreed that for the current scenario, clipping the lymph node with the intention of performing TAD + SLNB after NACT, based on the patient’s response, would be the most appropriate approach. This approach allows for the assessment of the axillary response to NACT and provides guidance for further axillary management. The combined synopsis highlighted the management of axillary involvement in cases of breast cancer receiving NACT. The panellists emphasised the importance of tailoring the treatment approach based on individual patient factors, response to therapy and the goal of achieving optimal oncological outcomes while preserving breast conservation whenever possible. CONCLUSION In conclusion, the webinar on ‘Sentinel Lymph Node Biopsy (SLNB) in Breast Cancer: Why, How, When and New Frontiers’ organised by BreastGlobal provided valuable insights into the current understanding and evolving frontiers of SLNB in breast cancer management. The speakers and panellists shared their expertise and research findings, highlighting the importance of evidence-based practices and the need for further studies to refine guidelines. Discussions revolved around the role of SLNB in different scenarios, including cases of DCIS, post-NACT and various novel techniques for SLNB. The poll results and panel discussions showcased the diversity of opinions and ongoing debates in the field. Overall, the webinar shed light on the complexities of axillary management in breast cancer and emphasised the significance of personalised approaches to optimise patient outcomes while minimising morbidity. Acknowledgements The authors would like to express their gratitude for unrestricted research support (Grant no #GC2528) provided by Bajaj Auto Ltd to Prashanti Cancer Care Mission (PCCM), through which BreastGlobal Platform and activities are conducted. The authors are very thankful to PCCM-CTCR staff for their invaluable support in making BreastGlobal webinars a huge success. The authors acknowledge the media support and technical help provided by our technical partners MixOrg, India. We greatly value the leadership and persistent support of BreastGlobal co-chairs, Dr. C.B. Koppiker and Prof. Chintamani. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Kothari et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: